PIK3CG and endometrial carcinoma: In contrast, Pilaralisib (SAR245408; XL147), another pan-PI3K inhibitor, used in a clinical trial of advanced or recurrent endometrial carcinomas, did not show any severe adverse events on patients but had only minimal anti-tumour activity ([115] NCT01013324).